Download PDF
Thromb Haemost 1979; 42(04): 1141-1152
DOI: 10.1055/s-0038-1657009
Symposium on Oral Anticoagulant Control
Schattauer GmbH Stuttgart

The Optimal Therapeutic Range in Oral Anticoagulation History and Proposal

E A Loeliger
The Leiden University Medical Centre, Department of Haematology, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
23 August 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

For patients on oral anticoagulation controlled with Quick’s prothrombin time test using rabbit brain thromboplastin American clinicians proposed in the early 1940s that the lower limit of prolongation be taken at 1.5 and the upper limit at 3, corresponding to 10-30 per cent prothrombin activity on a saline dilution curve. Thromboplastins derived from other tissues and species were later introduced, methods were modified, and adsorbed plasma was used instead of saline in the construction of the dilution curve to obtain percentage prothrombin activity; ratios and percentages lost their initial significance, but too often without the clinicians� awareness. With the detection of PIVKAs, finally, it became clear that transformation of prothrombin times into percentage activity, as obtained from dilution curves, could never be a valid means of standardization. It also became evident that only direct comparison of thromboplastins with (fresh) plasma from patients on stabilized oral anticoagulants could be used to determine equivalent therapeutic ranges for different types of thromboplastins. Reference thromboplastins were established and calibration procedures developed. A series of well-controlled clinical trials has provided sufficient information to define, in terms of these reference thromboplastins, therapeutic ranges for the prophylaxis and treatment of venous as well as arterial thrombosis. Definition of the ranges in terms of the biochemical defect induced by coumarin congeners remains, however, to be established.

 

  • References

  • 1 Allen EV. 1947; The clinical use of anticoagulants. Journal of the American Medical Association 134: 323
    CrossrefPubMedSearch in Google Scholar
  • 2 Allen EV, Barker NW, Waugh JM. 1942; A preparation from spoiled sweet clover. (3,3’- Methylene-Bis (4-Hydroxycoumarin)). Which prolongs coagulation and prothrombin time of the blood: a clinical study Journal of the American Medical Association 120: 1009
    CrossrefPubMedSearch in Google Scholar
  • 3 Bangham DR, Biggs R, Brozovic M, Denson KW E. 1973; Calibration of five different thromboplastins, using fresh and freeze-dried plasma. Thrombosis et Diathesis haemorrhagica 29: 228
    PubMedSearch in Google Scholar
  • 4 Bergqvist D, Dahlgren S. 1973; Leg vein thrombosis diagnosed by 125I-fibrinogen test in patients with fracture of the hip: a study of the effect of early prophylaxis with dicoumarol or dextran 70. VASA 2: 121
    PubMedSearch in Google Scholar
  • 5 Biggs R, Denson KW E. 1967; Third report on the standardization of the one-stage prothrombin time for the control of anticoagulant therapy. Thrombosis et Diathesis haemorrhagica supplement 26: 445
    PubMedSearch in Google Scholar
  • 6 Biggs R, Denson KW E. 1967; a Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. British Medical Journal 1: 84
    CrossrefPubMedSearch in Google Scholar
  • 7 Blackburn EK. 1977; Long-term anticoagulant therapy. Prescribes’ Journal 17: 73
    PubMedSearch in Google Scholar
  • 8 Boekhout-Mussert MJ, BriëT E, Brummelen Pvan, Lemkes HH P J, Loeliger EA. 1978; Arterial thromboembolic complications with aortic ball valve prostheses. American Heart Journal 95: 270
    PubMedSearch in Google Scholar
  • 9 Boekhout-Mussert MJ, Kolk-Schaap PJ Van Der, Hermans J, Loeliger EA. 1979 Prospective double-blind clinical trial of bovine, human, and rabbit thromboplastin in the control of long-term oral anticoagulation. Submitted for publication.
    PubMedSearch in Google Scholar
  • 10 Borchgrevink CF. 1960; Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta Medica Scandinavica 168 supplement (Suppl. 359) 1
    PubMedSearch in Google Scholar
  • 11 Boyles PW. 1968. Correlations of prothrombin test with haemorrhage and thromboembolism in patients on long-term anticoagulant therapy. Paper presented at the meeting of the American Therapeutic Society. San Francisco:
    Search in Google Scholar
  • 12 British Anticoagulant Panel Recommendation. 1974 Manchester Comparative Reagent and British Comparative Thromboplastin leaflet.
    PubMedSearch in Google Scholar
  • 13 Bronge A, Dahlgren S, Lindquist B. 1971; Prophylaxis against thrombosis in femoral neck fractures - a comparison between dextran 70 and dicoumarol. Acta chirurgica Scandinavica 137: 29
    PubMedSearch in Google Scholar
  • 14 Cleland J, Molloy PJ. 1973; Thromboembolic complications of the cloth-covered StarrEdwards prosthesis. No 2300 aortic and No 6300 mitral. Thorax 28: 41
    PubMedSearch in Google Scholar
  • 15 Coon WW, Willis PW, Symons MJ. 1969; Assessment of anticoagulant treatment of venous thromboembolism. Annals of Surgery 170: 559
    CrossrefPubMedSearch in Google Scholar
  • 16 Duckert F, Marbet GA. 1977; Die Kontrolle der oralen Antikoagulation - der therapeutische Bereich. Schweizerische Medizinische Wochenschrift 107: 1308
    PubMedSearch in Google Scholar
  • 17 EDITORIAL. 1971; Control of oral anticoagulant treatment. British Medical Journal 4: 317
    CrossrefPubMedSearch in Google Scholar
  • 18 General Diagnostics. 1974 Simplastin® leaflet.
    PubMedSearch in Google Scholar
  • 19 Goguel A. 1976; Contrôle de qualité du temps de Quick. Renseignements fournis par les confrontations interlaboratoires “Etalonorme” 1973 á 1975. Feuillets de Biologie 17: 31
    PubMedSearch in Google Scholar
  • 20 ICTH/ICSH (1979, 42, 1073): Prothrombin time standardization. Report of the Export on Oral Anticoagulant Control. The International Committee on Thrombosis and Haemostasis. The International Committee for Standardization in Haematology. Thrombosis and Haemostasis
    PubMed
  • 21 Johnson DH. 1976; Long term anticoagulant therapy following myocardial infarction. Minnesota Medicine 61: 333
    PubMedSearch in Google Scholar
  • 22 Kanis JA. 1974; Heparin in the treatment of pulmonary thromboembolism. Thrombosis et Diathesis haemorrhagica (Stuttg.) 32: 519
    PubMedSearch in Google Scholar
  • 23 Lam-Po-Tang PR L C, Poller L. 1975; Oral anticoagulant therapy and its control: an international survey. Thrombosis et Diathesis haemorrhagica (Stuttg.) 34: 419
    PubMedSearch in Google Scholar
  • 24 Linde DL Van Der. 1974. A controlled study of the preventing of thromboembolic complications by the use of coumarin d�riv�tes pre-operatively during the operation and postoperatively. In: Witkin E. (ed.) Venous Diseases Medical and Surgery management. American European Symposion on venous diseases. Foundation International Cooperation in the Medical Sciences; Montreux: p 223
    Search in Google Scholar
  • 25 Loeliger EA. 1973. Laboratory reagents and coagulation assay procedures. Bulletin Of The World Health Organization; 48 121
    Search in Google Scholar
  • 26 Loeliger EA, Boekhout-Mussert MJ, Bieger R. 1975; Prolonged continuous heparin treatment. Thrombosis et Diathesis haemorrhagica 33: 666
    PubMedSearch in Google Scholar
  • 27 Loeliger EA, Esch BVan Der, Mattern MJ, Brabander AS A Den. 1963; Behaviour of Factors II, VII, IX, and X during long-term treatment with coumarin. Thrombosis et Diathesis haemorrhagica 9: 75
    PubMedSearch in Google Scholar
  • 28 Loeliger EA, Halem-Visser LP Van. 1979; Biological properties of the thromboplastins and plasmas included in the ISCH/ICTH international cooperative prothrombin time standardization study. Thrombosis and Haemostasis 42: 1128
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Loeliger EA, Halem-Visser LP Van, Hemker HC. 1973; Plasma free of Factors II, VII, IX, and X. Need for high speed centrifugation after Al(OH)3-absorption Thrombosis et Diathesis haemorrhagica (Stuttg.) 29: 211
    PubMedSearch in Google Scholar
  • 30 Loeliger EA, Hensen A, Kroes F, Duk LM Van, Fekkes N, Jonge HDe, Hemker HC. 1967; A double-blind trial on long-term anticoagulant treatment after myocardial infarction. Acta Medica Scandinavica 182: 549
    PubMedSearch in Google Scholar
  • 31 Loeliger EA, Hensen A, Mattern MJ, Hemker HC. 1964; Behaviour of Factors II, VII, IX, and X in bleeding complications during long-term treatment with coumarin. Thrombosis et Diathesis haemorrhagica 10: 278
    PubMedSearch in Google Scholar
  • 32 Magath TB. 1939; Technic of the prothrombin time determination. American Journal of Clinical Pathology (technical supplement) 3: 187
    PubMedSearch in Google Scholar
  • 33 Matthews JM, Walker W. 1959; Control of anticoagulant therapy. A trial of Thrombotest. Lancet 2: 1159
    PubMedSearch in Google Scholar
  • 34 Medical Research Council. 1969; Assessment of short-term anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. British Medical Journal 1: 335
    PubMedSearch in Google Scholar
  • 35 Meuwissen OJ A T, Vervoorn AC, Cohen O, Jordan FL J, Nelemans FA. 1969; Double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Medica Scandinavica 186: 361
    PubMedSearch in Google Scholar
  • 36 Miale JB. 1962; Laboratory control of anticoagulant therapy. Journal of the American Medical Association 180: 106
    PubMedSearch in Google Scholar
  • 37 Moore CB, Beeler MF. 1961; Thrombotest versus one-stage prothrombin time determination. New England Journal of Medicine 264: 681
    CrossrefPubMedSearch in Google Scholar
  • 38 Moschos CB, Wong PC Y, SISE MS. 1964; Controlled study of the effective level of longterm anticoagulation. Journal of the American Medical Association 190: 799
    PubMedSearch in Google Scholar
  • 39 Nyegaard. 1974 Thrombotest® leaflet.
    PubMedSearch in Google Scholar
  • 40 Owren PA. 1959; Thrombotest. A new method for controlling anticoagulant therapy. Lancet 2: 754
    PubMedSearch in Google Scholar
  • 41 Owren PA, Aas K. 1951; The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scandinavian Journal of Clinical Laboratory Investigation 3: 201
    CrossrefPubMedSearch in Google Scholar
  • 42 Peyman MA. 1958; The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants. Acta Medica Scandinavica 162 suppl. 339
    PubMedSearch in Google Scholar
  • 43 Pinto DJ. 1970; Controlled trial of an anticoagulant (warfarin sodium) in the prevention of venous thrombosis following hip surgery. British Journal of Surgery 57: 349
    CrossrefPubMedSearch in Google Scholar
  • 44 Poller L. Wootliff. 1962; The value of capillary Thrombotest method for the control of longterm anticoagulant therapy. Thrombos. Haemostas. (Stuttgart) 7: 333
    PubMedSearch in Google Scholar
  • 45 Poller L. 1967; A national standard for anticoagulant therapy. The Manchester Comparative Reagent. Lancet 7: 491
    PubMedSearch in Google Scholar
  • 46 Poller L. 1976; British Comparative Thromboplastin therapeutic range. Thrombosis and Haemostasis (Stuttg.) 36: 485
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Poller L, Thomson JM, Yee KF. 1977; Stability studies on lyophilized reference thromboplastins for standardization of prothrombin times. Lancet 2: 1019
    PubMedSearch in Google Scholar
  • 48 Quick AJ. 1961; Clinical interpretation of the one-stage prothrombin time. Circulation 24: 1422
    CrossrefPubMedSearch in Google Scholar
  • 49 Quick AJ, Leu M. 1937; Quantitative determination of prothrombin. Journal of Biological Chemistry 119: 81
    PubMedSearch in Google Scholar
  • 50 Ratnoff OD. 1962; The laboratory control of anticoagulant therapy. Circulation 26: 321
    CrossrefPubMedSearch in Google Scholar
  • 51 Rogel S, Bassan MM. 1976; Anticoagulants in ischemic heart disease. Archives of Internal Medicine 136: 1229
    CrossrefPubMedSearch in Google Scholar
  • 52 Rozenberg MC, Firkin BG. 1965; “Thrombotest” and prothrombin time: a controlled clinical trial. Australasian Annals of Medicine 14: 3
    CrossrefPubMedSearch in Google Scholar
  • 53 Sevitt S, Innes D. 1964; Prothrombin time and Thrombotest in injured patients on prophylactic anticoagulant therapy. Lancet 1: 124
    PubMedSearch in Google Scholar
  • 54 Sise MS, Lavelle SM, Adamis D, Becker R. 1958; Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. New England Journal of Medicine 259: 266
    CrossrefPubMedSearch in Google Scholar
  • 55 Taberner DA, Poller L, Burslem RW, Jones JB. 1978; Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. British Medical Journal 1: 242
    CrossrefPubMedSearch in Google Scholar
  • 56 Tat RJ, Lewis AE. 1962; Levels of equivalence for various measurements of coumarin activity. Journal of the American Medical Association 180: 744
    CrossrefPubMedSearch in Google Scholar
  • 57 Tullis JL. 1976. Clot. Thomas CC. (ed.) Springfield, Illinois:
    Search in Google Scholar
  • 58 Vries WA DE, Tussen JG P, Jonge HDE, Loeliger EA, Roos J. (in preparation): Longterm anticoagulant therapy after myocardial infarction in the elderly patient.
    PubMed
  • 59 WHO proposed requirements for thromboplastins and plasmas used to control oral anticoagulant therapy. Requirements for Biological Substances No 28. Draft. 1978
    PubMedSearch in Google Scholar
  • 60 Wright IS, Beck DF, Marple CD. 1954; Myocardial infarction and its treatment with anticoagulants. Summary of findings in 1031 cases Lancet 7: 92
    PubMedSearch in Google Scholar
  • 61 Wright IS, Marple CD, Beck DF. 1948; Anticoagulant therapy of coronary thrombosis with myocardial infarction. Journal of the American Medical Association 134: 329
    PubMedSearch in Google Scholar
  • 62 Zucker S, Cathey MH, Sox PJ, Hall EC. 1970; Standardization of laboratory tests for controlling anticoagulant therapy. American Journal of Clinical Pathology 53: 348
    CrossrefPubMedSearch in Google Scholar